

Factors Associated with Psychotropic Medication Use in People Living with Dementia in the Community: A Systematic Review and Meta-Analysis

Kerryn L. Loftus¹, Anne P.F. Wand^{1,2}, Juanita L. Breen^{3,4}, Glenn E. Hunt², and Carmelle Peisah^{1,2,4}

¹ Discipline of Psychiatry and Mental Health, Faculty of Medicine & Health, University of New South Wales, NSW, Australia

² Specialty of Psychiatry, Faculty of Medicine and Health, University of Sydney, NSW, Australia

³ Wicking Dementia Research and Education Centre, College of Health and Medicine, University of Tasmania, Hobart, Tasmania, Australia

⁴ Capacity Australia, Australian Centre for Capacity, Ethics and the Prevention of Exploitation of People with Disabilities, NSW, Australia

Corresponding author: Dr. Kerryn Loftus

JARA UNIT, Concord Centre for Mental Health, Concord Hospital, 1 Hospital Road, Concord 2137 NSW, Australia

k.loftus@unsw.edu.au

Journal: *Drugs & Aging*

UPDATED MEDLINE SEARCH HISTORY NOV 2021

Database:

MEDLINE(R) including Daily update <1996-current>

#	Query	Results from 08 Nov 2021
1	Alzheimer Disease/	85,135
2	"dementia".mp.	95,743
3	*"Psychotropic Drugs"/	8,585
4	1 or 2	155,065
5	exp Antidepressive Agents/	89,207
6	exp Psychotropic Drugs/	199,271
7	Antipsychotic Agents/	43,233
8	Anti-Anxiety Agents/ or Benzodiazepines/	23,762
9	Analgesics, Opioid/	45,394
10	Psychotropic Drugs/	12,676
11	exp Residence Characteristics/	56,171
12	dwel*.mp.	36,942
13	home.mp.	176,856
14	Independent Living/	7,491
15	3 or 5 or 6 or 7 or 8 or 9 or 10	246,563
16	exp Residence Characteristics/	56,171
17	"community dwelling".mp.	21,252
18	11 or 14 or 16 or 17	71,335
19	4 and 15 and 18	147
20	limit 19 to (english language and full text and humans and yr="2010 -Current")	44

Alzheimer Disease/
"dementia".mp.
*"Psychotropic Drugs"/
1 or 2
exp Antidepressive Agents/
exp Psychotropic Drugs/
Antipsychotic Agents/
Anti-Anxiety Agents/ or Benzodiazepines/
Analgesics, Opioid/
Psychotropic Drugs/
exp Residence Characteristics/
dwell*.mp.
home.mp.
Independent Living/
3 or 5 or 6 or 7 or 8 or 9 or 10
exp Residence Characteristics/
"community dwelling".mp.
11 or 14 or 16 or 17
4 and 15 and 18
limit 19 to (english language and full text and humans and yr="2010-Current")

Table S1. Logit event rates of antipsychotic treatment according to respite allowance and psychiatric comorbidity

				Effect size (Logit event rate) with 95% Confidence Intervals						
Groups	Number of studies	Event rate Random	Event rate Fixed	Point estimate	Standard error	Variance	Lower limit	Upper limit	Within group heterogeneity	Between group heterogeneity
Prevalence	17	0.150	0.204	-1.361	0.003	0.001	-1.366	-1.355	Q=9308, df(Q)=16 P<0.001, I ² =99.8	
Accommodation*										
Home	13	0.140	0.131	-1.896	0.009	0.001	-1.913	-1.878	Q=3912, df(Q)=12 P<0.001, I ² =99.7	Q*=4.85, df(Q)=1 P=0.028
Respite	3	0.217	0.213	-1.309	0.003	0.001	-1.314	-1.303	Q=1213, df(Q)=2 P<0.001, I ² =99.8	
Psychiatric Diagnosis										
None	4	0.082	0.084	-2.395	0.018	0.001	-2.431	-2.359	Q=256, df(Q)=3 P<0.001, I ² =98.8	Q*=15.0, df(Q)=2 P=0.001
Not stated	7	0.182	0.209	-1.332	0.003	0.001	-1.338	-1.327	Q=4569, df(Q)=6 P<0.001, I ² =99.9	
Yes	6	0.180	0.190	-1.448	0.011	0.001	-1.468	-1.427	Q=1120, df(Q)=5 P<0.001, I ² =99.6	

*One study (Kester-17) was excluded from this analysis as type of accommodation was not stated/reported in the article.

Note. Effect size estimates on fixed effects model. Q* mixed-method Q value

Table S2. Logit event rates of antidepressant treatment according to respite allowance or psychiatric comorbidity

				Effect size (Logit event rate) with 95% Confidence Intervals						
Groups	Number of studies	Event rate Random	Event rate Fixed	Point estimate	Standard error	Variance	Lower limit	Upper limit	Within group heterogeneity	Between group heterogeneity
Prevalence	10	0.343	0.474	-0.106	0.002	0.001	-0.110	-0.101	Q=16960, df(Q)=9 P<0.001, I ² =99.9	
Accommodation										
Home	7	0.330	0.322	-0.745	0.011	0.001	-0.766	-0.724	Q=85, df(Q)=6 P<0.001, I ² =92.9	Q*=0.42, df(Q)=1 P<0.519 (NS)
Respite	3	0.390	0.481	-0.078	0.002	0.001	-0.082	-0.074	Q=13178 df(Q)=2 P<0.001, I ² =99.9	
Psychiatric Diagnosis										
None/Not stated	5	0.345	0.476	-0.095	0.002	0.001	-0.099	-0.090	Q=15458 df(Q)=4 P<0.001, I ² =99.9	Q*=0.01 df(Q)=1 P=0.976 (NS)
Yes	5	0.343	0.352	-0.608	0.015	0.001	-0.638	-0.579	Q=359 df(Q)=4 P<0.001, I ² =98.9	
Country										
Non-USA	7	0.329	0.293	-0.882	0.007	0.001	-0.895	-0.869	Q=1218, df(Q)=6 P<0.001, I ² =99.5	Q*=0.7 df(Q)=1 P=0.408 (NS)
USA	3	0.385	0.498	-0.009	0.002	0.001	-0.013	-0.004	Q=88, df(Q)=2 P<0.001, I ² =97.7	

Note. Effect size estimates on fixed effects model. Q* mixed-method Q value

Table S3. Logit event rates of anxiolytic/hypnotic treatment according to respite allowance or psychiatric comorbidity

				Effect size (Logit event rate) with 95% Confidence Intervals						
Groups	Number of studies	Event rate Random	Event rate Fixed	Point estimate	Standard error	Variance	Lower limit	Upper limit	Within group heterogeneity	Between group heterogeneity
Prevalence	9	0.251	0.277	-0.959	0.002	0.001	-0.964	-0.954	Q=5316, df(Q)=8 P<0.001, I ² =99.9	
Accommodation										
Home	6	0.242	0.434	-0.267	0.010	0.001	-0.287	-0.247	Q=467, df(Q)=5 P<0.001, I ² =98.9	Q*=0.91, df(Q)=1 P=0.341 (NS)
Respite	3	0.270	0.269	-1.000	0.003	0.001	-1.005	-0.995	Q=45, df(Q)=2 P=0.001, I ² =95.6	
Country										
Non-USA	6	0.286	0.335	-0.684	-0.006	0.001	-0.696	-0.671	Q=3103, df(Q)=5 P<0.001, I ² =99.8	Q*=3.11, df(Q)=1 P=0.078 (NS)
USA	3	0.173	0.268	-1.005	0.003	0.001	-1.010	-1.000	Q=65, df(Q)=2 P<0.001, I ² =96.9	

Note. Effect size estimates on fixed effects model. Q* mixed-method Q value